Surfactant Replacement. Present and Future.

The Newborn Lung

Volumn , Issue , 2012, Pages 283-299

  Speer, Christian P ^a   Sweet, David ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b ROYAL MATERNITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870358696     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2682-4.00014-7     Document Type: Chapter

References (121)

1. Engle WA Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008, 121:419-432. American Academy of Pediatrics Committee on Fetus and Newborn.
2. Sweet DG, Carnielli V, Greisen G, et al. European Association of Perinatal Medicine. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2010 update. Neonatology 2010, 97:402-417.
3. Fujiwara T, Maeta H, Chida S, et al. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980, 1:55-59.
4. Halliday HL History of surfactant from 1980. Biol Neonate 2005, 87:317-322.
5. Soll R Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews 1999, 4. CD001456.
6. Soll R, Özek E Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews 2009, 1. CD000141.
7. Sweet D, Bevilacqua G, Carnielli V, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome. J Perinat Med 2007, 35:175-186.
8. Seger N, Soll R Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2009, 2. CD007836.
9. Soll R Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database of Systematic Reviews 1998, 3. CD001149.
10. Soll R, Blanco F Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews 2001, 2. CD000144.
11. Strayer DS, Merritt TA, Hallman M Surfactant replacement: immunological considerations. Eur Respir J Suppl 1989, 3:91s-96s.
12. Whitsett JA, Hull WM, Luse S Failure to detect surfactant protein specific antibodies in sera of premature infants treated with Survanta, a modified bovine surfactant. Pediatrics 1997, 87:505-510.
13. Cochrane CG Surfactant protein B and mimic peptides in the function of pulmonary surfactant. FEBS Lett 1998, 430:424-425.
14. Revak SD, Merritt TA, Cochrane CG, et al. Efficacy of synthetic peptide containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res 1996, 39:715-724.
15. Cochrane CG, Revak SD, Merritt TA, et al. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996, 153:404-410.
16. Moya FR, Gadzinowski J, Bancalari E, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005, 115:1018-1029.
17. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005, 115:1030-1038.
18. Kattwinkel J Synthetic surfactants: the search goes on. Pediatrics 2005, 115:1075-1076.
19. Bloom BT, Clark RH Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics 2005, 116:392-399. Infasurf Survanta Clinical Trial Group.
20. Bloom BT, Kattwinkel J, Hall RT, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997, 100:31-38.
21. Ramanathan R, Rasmussen MR, Gerstmann DR, et al. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004, 21:109-119.
22. Speer CP, Gefeller O, Groneck P, et al. Randomized clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 1995, 72:F8-F13.
23. Halliday HL History of surfactant from 1980. Biol Neonate 2005, 87:317-322.
24. Ikegami M, Adams FH, Towers B, Osher AB The quantity of natural surfactant necessary to prevent the respiratory distress syndrome in premature lambs. Pediatr Res 1980, 14:1082-1085.
25. Fujiwara T, Konishi M, Chida S, et al. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. Pediatrics 1990, 86:753-764.
26. Horbar JD, Soll RF, Sutherland JM, et al. A multicenter, randomized, placebo-controlled trial of surfactant therapy for respiratory distress syndrome. N Engl Jof Med 1989, 320:959-965.
27. Svenningsen N, Robertson B, Andreason B, et al. Endotracheal administration of surfactant in very low birth weight infants with respiratory distress syndrome. Critical Care Medicine 1987, 15:918.
28. Collaborative European Multicenter Study Group Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 1988, 82:683-691.
29. Gortner L, Bernsau U, Hellwege HH, et al. A multicenter randomized controlled clinical trial of bovine surfactant for prevention of respiratory distress syndrome. Lung 1990, 168(Suppl):864-869.
30. Phibbs RH, Ballard RA, Clements JA, et al. Initial clinical trial of Exosurf, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Pediatrics 1991, 88:1-9.
31. Konishi M, Fujiwara T, Naito T, et al. Surfactant replacement therapy in neonatal respiratory distress syndrome. A multi-centre, randomized clinical trial: comparison of high- versus low-dose of surfactant TA. Eur J Pediatr 1988, 147:20-25.
32. Gortner L, Pohlandt F, Bartmann P, et al. High-dose versus low-dose bovine surfactant treatment in very premature infants. Acta Paediatr 1994, 83:135-141.
33. Halliday HL, Tarnow-Mordi WO, Corcoran JD, Patterson CC Multicentre randomized trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child 1993, 69:276-280.
34. Torresin M, Zimmermann LJ, Cogo PE, et al. Exogenous surfactant kinetics in infant respiratory distress syndrome: A novel method with stable isotopes. Am J Respir Crit Care Med 2000, 161:1584-1589.
35. Cogo PE, Facco M, Simonato M, et al. Dosing of porcine surfactant: effect on kinetics and gas exchange in respiratory distress syndrome. Pediatrics 2009, 124:e950-e957.
36. Malloy CA, Nicoski P, Muraskas JK A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr 2005, 94:779-784.
37. Seger N, Soll R Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2009, 2. CD007836.
38. Soll R Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews 1999, 4. CD001456.
39. Soll R, Morley CJ Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 2001, I(2). CD000510.
40. Kattwinkel J, Bloom BT, Delmore P, et al. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics 1993, 92:90-98.
41. Kendig JW, Ryan RM, Sinkin RA, et al. Comparison of two strategies for surfactant prophylaxis in very premature infants: a multicenter randomized trial. Pediatrics 1998, 101:1006-1012.
42. Avery ME, Tooley WH, Keller JB, et al. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 1987, 79:26-30.
43. De Klerk AM, De Klerk RK Nasal continuous positive airway pressure and outcomes of preterm infants. J Paediatr Child Health 2001, 37:161-167.
44. Morley CJ, Davis PG, Doyle LW, et al. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008, 358:700-708.
45. Sandri F, Plavka R, Ancora G, et al. Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics 2010, 125:e1402-e1409.
46. Finer NN, Carlo WA, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010, 362:1970-1979. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network.
47. Speer CP, Robertson B, Curstedt T, et al. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 1992, 89:13-20.
48. Dunn MS, Shennan AT, Possmayer F Single- versus multiple-dose surfactant replacement therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome. Pediatrics 1990, 86:564-571.
49. The OSIRIS Collaborative Group Early versus delayed neonatal administration of a synthetic surfactant-the judgment of OSIRIS. Lancet 1992, 340:1363-1379.
50. Soll RF Multiple versus single dose natural surfactant extract for severe neonatal respiratory distress syndrome. Cochrane Database Syst Rev 1999, 2. CD000141.
51. Kattwinkel J, Bloom BT, Delmore P, et al. High-versus low-threshold surfactant retreatment for neonatal respiratory distress syndrome. Pediatrics 2000, 106:282-288.
52. Fetus and Newborn Committee, Canadian Paediatric Society (CPS) Recommendations for neonatal surfactant therapy. J Paediatr Child Health 2005, 10:109-116.
53. Segerer H, van Gelder W, Angenent FW, et al. Pulmonary distribution and efficacy of exogenous surfactant in lung-lavaged rabbits are influenced by the instillation technique. Pediatr Res 1993, 34:490-494.
54. Valls-i-Soler A, Fernández-Ruanova B, López-Heredia y Goya J, et al. A randomized comparison of surfactant dosing via a dual-lumen endotracheal tube in respiratory distress syndrome. The Spanish Surfactant Collaborative Group. Pediatrics 1998, 101:E4.
55. Stevens TP, Blennow M, Myers EH, Soll R Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database of Systematic Reviews 2007, 4. CD003063.
56. Verder H, Albertsen P, Ebbesen F, et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation. Pediatrics 1999, 103:E24.
57. O'Donnell CP, Kamlin CO, Davis PG, Morley CJ Endotracheal intubation attempts during neonatal resuscitation: success rates, duration, and adverse effects. Pediatrics 2006, 117:e16-e21.
58. O'Donnell CP, Davis PG, Lau R, et al. Neonatal resuscitation 2: an evaluation of manual ventilation devices and face masks. Arch Dis Child Fetal Neonatal Ed 2005, 90:F392-F396.
59. Hillman NH, Kallapur SG, Pillow JJ, et al. Airway injury from initiating ventilation in preterm sheep. Pediatr Res 2010, 67:60-65.
60. Ingimarsson J, Björklund LJ, Curstedt T, et al. Incomplete protection by prophylactic surfactant against the adverse effects of large lung inflations at birth in immature lambs. Intensive Care Med 2004, 30:1446-1453.
61. Speer CP Chorioamniotitis, postnatal factors and proinflammatory response in the pathogenetic sequence of bronchopulmonary dysplasia. Neonatology 2009, 95:353-361.
62. Cosmi EV, La Torre R, Piazze JJ, et al. Intraamniotic surfactant for prevention of neonatal respiratory distress syndrome (IRDS): rationale and personal experience. Eur J Obstet Gynecol Reprod Biol 1997, 71:135-139.
63. Zhang JP, Wang YL, Wang YH, et al. Prophylaxis of neonatal respiratory distress syndrome by intra-amniotic administration of pulmonary surfactant. Chin Med J (Engl) 2004, 117:120-124.
64. Abdel-Latif ME, Osborn DA, Challis D Intra-amniotic surfactant for women at risk of preterm birth for preventing respiratory distress in newborns. Cochrane Database of Systematic Reviews 2010, 1. CD007916.
65. Kattwinkel J, Robinson M, Bloom BT, et al. Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. J Perinatol 2004, 24:360-365.
66. Trevisanuto D, Grazzina N, Ferrarese P, et al. Laryngeal mask airway used as a delivery conduit for the administration of surfactant to preterm infants with respiratory distress syndrome. Biol Neonate 2005, 87:217-220.
67. Dijk PH, Heikamp A, Bambang Oetomo S Surfactant nebulisation prevents the adverse effects of surfactant therapy on blood pressure and cerebral blood flow in rabbits with severe respiratory failure. Intensive Care Med 1997, 23:1077-1081.
68. Berggren E, Liljedahl M, Winbladh B, et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr 2000, 89:460-464.
69. Sun Y, Yang R, Zhong JG, et al. Aerosolised surfactant generated by a novel noninvasive apparatus reduced acute lung injury in rats. Crit Care 2009, 13:R31.
70. Finer NN, Merritt TA, Bernstein G, et al. An open label, pilot study of Aerosurf combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv 2010, 23:303-309.
71. Kribs A, Pillekamp F, Hünseler C, et al. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age
72. Herting E, Kribs A, Roth B, et al. Surfactant via gastric tube in spontaneously breathing very low birth weight infants on nasal CPAP prevents mechanical ventilation. Neonatology 2010, 97:395.
73. Dargaville PA, Copnell B The epidemiology of meconium aspiration syndrome: incidence, risk factors, therapies, and outcome. Pediatrics 2006, 117:1712-1721. Australian and New Zealand Neonatal Network.
74. Qian L, Liu C, Zhuang W, et al. Neonatal Respiratory Failure: A 12-Month Clinical Epidemiologic Study From 2004 to 2005 in China. Pediatrics 2008, 121:e1115-e1124.
75. Wirbelauer J, Speer CP The role of surfactant treatment in preterm infants and term newborns with acute respiratory distress syndrome. J Perinatol 2009, 29(Suppl 2):S18-S22.
76. Moses D, Holm BA, Spitale P, et al. Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 1991, 164:477-481.
77. Auten RL, Notter RH, Kendig JW, et al. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991, 87:101-107.
78. Paranka MS, Walsh WF, Stancombe BB Surfactant lavage in a piglet model of meconium aspiration syndrome. Pediatr Res 1992, 31:625-628.
79. El Shahed AI, Dargaville P, Ohlsson A, Soll RF Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database Syst Rev 2007, 3. CD002054.
80. Dargaville PA, Copnell B, Tingay DG, et al. Refining the method of therapeutic lung lavage in meconium aspiration syndrome. Neonatology 2008, 94:160-163.
81. Dargaville PA, Copnell B, Mills JF, et al. Randomized controlled trial of lung lavage with dilute surfactant for meconium aspiration syndrome. J Pediatr 2010, 158:383-389. e2.
82. Taeusch HW, Lu KW, Goerke J, Clements JA Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med 1999, 159:1391-1395.
83. Stichtenoth G, Jung P, Walter G, et al. Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro. Pediatr Res 2006, 59:407-411.
84. Lu KW, Robertson B, Taeusch HW Dextran or polyethylene glycol added to Curosurf for treatment of meconium lung injury in rats. Biol Neonate 2005, 88:46-53.
85. Calkovska A, Mokra D, Drgova A, et al. Bronchoalveolar lavage with pulmonary surfactant/dextran mixture improves meconium clearance and lung functions in experimental meconium aspiration syndrome. Eur J Pediatr 2008, 167:851-857.
86. Lu KW, Taeusch HW Combined effects of polymers and KL(4) peptide on surface activity of pulmonary surfactant lipids. Biochim Biophys Acta 2010, 1798:1129-1134.
87. Herting E, Gefeller O, Land M, et al. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics 2000, 106:957-964.
88. Speer CP, Robertson B, Halliday HL Commentary: Randomized trial comparing natural and synthetic surfactant: Increased infection rate after natural surfactant?. Acta Paediatr 2000, 89:510-512.
89. Speer CP, Götze B, Robertson B, Curstedt T Phagocytic functions and TNF secretion of human monocytes exposed to natural porcine surfactant (Curosurf). Pediatr Res 1991, 30:69-74.
90. Herting E, Sun B, Jarstrand C, et al. Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia. Arch Dis Child Fetal Neonatal Ed 1997, 76:F3-F8.
91. Herting E, Gan X, Rauprich P, et al. Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B streptococcal pneumonia. Am J Respir Crit Care Med 1999, 159:1862-1867.
92. Stichtenoth G, Linderholm B, Björkman MH, et al. Prophylactic intratracheal polymyxin B/surfactant prevents bacterial growth in neonatal E. coli pneumonia of rabbits. Pediatr Res 2010, 67:369-374.
93. Suen HC, Catlin EA, Ryan DP, et al. Biochemical immaturity of lungs in congenital diaphragmatic hernia. J Pediatr Surg 1993, 28:471-475.
94. Glick PL, Stannard VA, Leach CL, et al. Pathophysiology of congenital diaphragmatic hernia II: the fetal lamb CDH model is surfactant deficient. J Pediatr Surg 1992, 27:382-387.
95. IJsselstijn H, Zimmermann LJ, Bunt JE, et al. Prospective evaluation of surfactant composition in bronchoalveolar lavage fluid of infants with congenital diaphragmatic hernia and of age-matched controls. Crit Care Med 1998, 26:573-580.
96. Boucherat O, Benachi A, Chailley-Heu B, et al. Surfactant maturation is not delayed in human fetuses with diaphragmatic hernia. PLoS Med 2007, 4:e237.
97. Cogo PE, Zimmermann LJ, Verlato G, et al. A dual stable isotope tracer method for the measurement of surfactant disaturated-phosphatidylcholine net synthesis in infants with congenital diaphragmatic hernia. Pediatr Res 2004, 56:184-190.
98. Janssen DJ, Zimmermann LJ, Cogo P, et al. Decreased surfactant phosphatidylcholine synthesis in neonates with congenital diaphragmatic hernia during extracorporeal membrane oxygenation. Intensive Care Med 2009, 35:1754-1760.
99. O'Toole SJ, Karamanoukian HL, Sharma A, et al. Surfactant rescue in the fetal lamb model of congenital diaphragmatic hernia. J Pediatr Surg 1996, 31:1105-1108.
100. Glick PL, Leach CL, Besner GE, et al. Pathophysiology of congenital diaphragmatic hernia. III: Exogenous surfactant therapy for the high-risk neonate with CDH. J Pediatr Surg 1992, 27:866-869.
101. Van Meurs K Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia?. J Pediatr 2004, 145:312-316. Congenital Diaphragmatic Hernia Study Group.
102. Soll R, Ozek E Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2010, 1. CD001079.
103. Holm BA, Notter RH Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J Appl Physiol 1987, 63:1434-1442.
104. Pandit PB, Dunn MS, Colucci EA Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics 1995, 95:32-36.
105. Amizuka T, Shimizu H, Niida Y, Ogawa Y Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema. Eur J Pediatr 2003, 162:697-702.
106. Aziz A, Ohlsson A Surfactant for pulmonary hemorrhage in neonates. Cochrane Database of Systematic Reviews 2008, 2. CD005254.
107. Khammash H, Perlman M, Wojtulewicz J, Dunn M Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993, 92:135-139.
108. Lotze A, Knight GR, Martin GR, et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr 1993, 122:261-268.
109. Lotze A, Mitchell BR, Bulas DI, et al. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J Pediatr 1998, 132:40-47.
110. Hintz SR, Suttner DM, Sheehan AM, et al. Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): how new treatment modalities have affected ECMO utilization. Pediatrics 2000, 106:1339-1343.
111. Luchetti M, Ferrero F, Gallini C, et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr Crit Care Med 2002, 3:261-268.
112. Busani S, Girardis M, Biagioni E, et al. Surfactant therapy and intravenous zanamivir in severe respiratory failure due to persistent influenza A/H1N1 2009 virus infection. Am J Respir Crit Care Med 2010, 182:1334.
113. Varisco BM, Palmatier CM, Alten JA Reversal of intractable hypoxemia with exogenous surfactant (calfactant) facilitating complete neurological recovery in a pediatric drowning victim. Pediatr Emerg Care 2010, 26:571-573.
114. Verder H, Ebbesen F, Linderholm B, et al. Prediction of respiratory distress syndrome by the microbubble stability test on gastric aspirates in newborns of less than 32 weeks' gestation. Acta Paediatr 2003, 92:728-733.
115. Daniel IW, Fiori HH, Piva JP, et al. Lamellar body count and stable microbubble test on gastric aspirates from preterm infants for the diagnosis of respiratory distress syndrome. Neonatology 2010, 98:150-155.
116. Verder H, Ebbesen F, Brandt J, et al. Lamellar body counts on gastric aspirates for prediction of respiratory distress syndrome. Acta Paediatr 2011, 100:175-180.
117. Almlén A, Walther FJ, Waring AJ, et al. Synthetic surfactant based on analogues of SP-B and SP-C is superior to single-peptide surfactants in ventilated premature rabbits. Neonatology 2010, 98:91-99.
118. Curstedt T, Johansson J Different effects of surfactant proteins B and C-implications for development of synthetic surfactants. Neonatology 2010, 97:367-372.
119. Lu KW, Taeusch HW Combined effects of polymers and KL(4) peptide on surface activity of pulmonary surfactant lipids. Biochim Biophys Acta 2010, 1798:1129-1134.
120. Yeh TF, Lin HC, Chang CH, et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics 2008, 121:e1310-e1318.
121. Kuo HT, Lin HC, Tsai CH, et al. A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants. J Pediatr 2010, 156:537-541.